Authors
Latest:
Supporting Cancer Survivors: The Clinician's RoleAmy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.
Latest:
World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and TreatmentLynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.
Latest:
Pembrolizumab’s Potential in Treating Richter Transformation of CLLYucai Wang, MD, PhD, discusses the rationale, methods, and design of a study evaluating the efficacy of pembrolizumab when given as both a monotherapy and in combination with B-cell receptor inhibitors for Richter transformation of CLL.
Latest:
Tazemetostat Shows Benefit in EZH2-Mutated Follicular LymphomaConnie L. Batlevi, MD, PhD, discusses the efficacy of tazemetostat in patients with follicular lymphoma and an EZH2 mutation.
Latest:
Safety Challenges of Oncolytic Virus TherapyAs part of its Speaking Out series, Patrick Wagner, MD, discusses safety concerns regarding oncolytic viral therapy.
Latest:
Where Does Inhibition of BCL-2 Family Proteins Fit into the Multiple Myeloma Treatment Landscape?Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.
Latest:
New Research Challenges ASCT Sequencing in Refractory AMLJohannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/
Latest:
Novel Agents/Combinations for aRCCMatthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.
Latest:
Less Toxic, More Personalized Treatments on the Horizon in HER2+ Breast CancerNaomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.
Latest:
Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBCResults from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.
Latest:
PR-Driven Approaches to Treating Granulosa Cell TumorsEven though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.
Latest:
PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial ToxicityRoss F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.
Latest:
No Increase of Grade 3/4 AEs Seen With Polatuzumab Vedotin Plus R-mini-CHOP in DLBCLThe use of polatuzumab vedotin in place of vincristine in R-mini-CHOP may lead to an increase in gastrointestinal adverse events in frail patients with diffuse large B-cell lymphoma.
Latest:
Rashdan Explores the Safety/Efficacy of Osimertinib and SABR in EGFR+ NSCLCSawsan Rashdan, MD, discusses the background, findings, and next steps of a phase 2 study evaluating treatment with osimertinib and consolidative SABR for the treatment of EGFR-mutated NSCLC.
Latest:
Advances in the Treatment of SarcomasLisa B. Ercolano, MD, discusses some of the advances that have been seen in the treatment of sarcomas.
Latest:
Soiffer Discusses Relapse After TransplantRobert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.
Latest:
Hypofractionated Radiation Shows Comparable Lymphedema Risk to Standard Therapy in Early Breast CancerThe phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.
Latest:
Tisotumab Vedotin Improves Treatment Options in Cervical CancerSusan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.
Latest:
Emerging TRK Inhibitors Are Explored Across Cancer SettingsTargeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to target the BCR-ABL fusion in chronic myelogenous leukemia.
Latest:
Incidence of ESR1 mutations and best practices for testingAlong with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1m mutations at both the initial diagnosis of metastatic breast cancer (MBC) and at each subsequent progression using liquid biopsy assays.
Latest:
Key Updates in Lower-Risk MDSIn the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.
Latest:
JAK Inhibitors Emerge as a Cornerstone Therapy for MyelofibrosisWith multiple JAK inhibitors now available to choose from, patient- and disease-specific factors are vital in determining the most appropriate therapy for patients with myelofibrosis.
Latest:
Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic StrategyIn the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.
Latest:
Updated Zanidatamab Data Shows Durable Response in Biliary Tract CancerShubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer treatment.
Latest:
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCCIn this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Latest:
About NRG GY018: Pembrolizumab Plus Chemotherapy in Endometrial CancerJohn Nakayama, MD, discusses the significance of the NRG GY018 study in endometrial cancer.
Latest:
Optimizing Treatment in Myeloma With Biweekly Dosing of TalquetamabCesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.
Latest:
Updates in the Management of Diffuse Large B-Cell LymphomaYazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.
Latest:
Ovarian Function Suppression Improves Survival in Premenopausal Women with HR+, HER2+ Breast CancerSun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress.
Latest:
In Advanced Prostate Cancer, a String of Modest Gains Are Changing Patient CareRobert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.
